In the past two weeks, Canopy Growth, Cronos and Aphria have all announced significant changes in plans for their Australian operations.

After several names in the Canadian cannabis space invested early into Australia, some firms are choosing to adjust their plans with respect to the country’s burgeoning medical marijuana sector.

In the past two weeks, Canopy Growth (NYSE:CGC,TSX:WEED), Cronos Group (NASDAQ:CRON,TSX:CRON) and Aphria (NYSE:APHA,TSX:APHA) all announced a significant change in plans for their Australian operations. Aphria’s was the most recent, coming on Wednesday (October 23).

Aphria is reportedly looking to sell 37 million shares of its minority stake in Australian cannabis producer Althea Group Holdings (ASX:AGH), according to a report from Australian Financial Review.

The Ontario-based company has a total of 50.1 million shares, representing a 25 percent ownership stake in Althea.

Aphria originally invested C$2.5 million in the Melbourne cannabis firm back in 2018, allowing Aphria to sell marijuana products into Australia’s medical cannabis space.

In 2018, Althea received cultivation and manufacturing licenses and also launched its initial public offering (IPO) to list on the Australian Securities Exchange (ASX).

Cannabis giant Canopy Growth also announced it was divesting its stake in an Australia-based marijuana company.

Canopy Growth confirmed the sale of its 13.2 percent interest in AusCann Group Holdings (ASX:AC8), or over 42 million shares, ending the three-year relationship between the two firms. The company came away with C$6.3 million from the sale.

“The decision to divest our position in AusCann … will allow us to sharpen our focus on our wholly-owned operations in the market, while continuing to collaborate with our partners at AusCann,” Canopy Growth CEO Mark Zekulin said in the press release.

Cronos Group will split up with its Australian division by way of a new listing. Cronos Australia, a joint venture with NewSouthern Capital, plans to issue 40 million shares at AU$0.50 a piece ahead of its listing on the ASX, where it expects to list by November 11.

Like Aphria, Cronos plans on helping its Australian counterpart develop its position in the Australian cannabis landscape, according to Cronos Chairman and CEO Mike Gorenstein.

In a prospectus for the proposed company, it is noted that Cronos Australia seeks to lead the health and wellness space in the Asia-Pacific region, which will include export opportunities to New Zealand, though the distribution of tetrahydrocannabinol and cannabidiol products.

Medical marijuana was first legalized in the country in 2016 and since then the sector has grown. A report from Prohibition Partners projected medical cannabis in the country could be worth up to US$2.1 billion by 2028. In September, the Australian Capital Territory became the first region in Australia to fully legalize the recreational use of marijuana.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

How to Access Medical Cannabis in Australia

Recreational cannabis remains out of reach in Australia, but the country legalised medical cannabis in 2016, opening up access to the cannabis market for both Australians and investors alike.

Cannabis in Australia is used to treat a myriad of conditions, from epilepsy to neuropathic pain, but federal legislation has a strict hold on the distribution of cannabis in the country.

Patients can only receive medicinal cannabis products via a specialist and then may have to wait up to a month for government approval. However, there are signs that the limits to access are slowly lessening, including the approval of over-the-counter cannabidiol (CBD) products and new breakthroughs in government-sponsored medical cannabis research.

Keep reading... Show less

Australia Mining Update: H1 2021 in Review

Click here to read the previous Australia mining update.

After an uncertain 2020 for the Australian mining industry, the resource market showed signs of a sharp recovery in the first six months of the new year.

Prices for iron ore are supporting resource exports in the country, with many ASX-listed mining companies also posting gains year-to-date.

Here the Investing News Network looks at what's happened in Australia's mining sector so far in 2021, and what could be ahead in the second half.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

Investing in Lithium in Australia

After the country became the world’s largest lithium producer in 2018, many market participants are wondering if investing in lithium in Australia is a good option

Without a doubt, the energy revolution is here to stay, with forecasts for electric vehicle (EV) sales increasing every day. As a result, demand for lithium, a key element in the lithium-ion batteries used to power electric cars, is expected to triple by 2025 — reaching about 1 million tonnes in size.

For investors interested in getting into the space, here’s a brief overview of the basic facts to know about investing in lithium in Australia, including what stocks to keep an eye on.

Keep reading... Show less

How to Buy Bitcoin in Australia

Investors looking for decentralised assets (and potentially major gains) in a post-COVID-19 Australia are turning in droves to cryptocurrencies.

Bitcoin in particular is getting Aussies excited after its price hit record highs in March 2021, and again the next month. As a finite resource, its volatility is proving exciting for many market watchers.

For those interested in jumping into the space, the Investing News Network has put together a step-by-step guide on how to start buying bitcoin in Australia — and how to stay safe while doing so.

Keep reading... Show less

How to Access Medical Cannabis in Australia

Recreational cannabis remains out of reach in Australia, but the country legalised medical cannabis in 2016, opening up access to the cannabis market for both Australians and investors alike.

Cannabis in Australia is used to treat a myriad of conditions, from epilepsy to neuropathic pain, but federal legislation has a strict hold on the distribution of cannabis in the country.

Patients can only receive medicinal cannabis products via a specialist and then may have to wait up to a month for government approval. However, there are signs that the limits to access are slowly lessening, including the approval of over-the-counter cannabidiol (CBD) products and new breakthroughs in government-sponsored medical cannabis research.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

When Will Australia Legalise Recreational Cannabis?

Recreational cannabis remains illegal in all Australia’s states and territories with the exception of the Australian Capital Territory (ACT). But could that change in the future?

So far there are no clear indicators as to when or if Australia could legalise recreational cannabis, but attitudes seem to be changing. Public support is growing, and there’s even some political acceptance.

Read on to learn more about when Australia may legalise recreational cannabis.

Keep reading... Show less

A State-by-State Guide to Cannabis in Australia

Australia made waves when it federally legalised medicinal cannabis in 2016, and its marijuana market has experienced significant growth since then.

A study from FreshLeaf Analytics pegs Australian medical market sales at AU$95 million in 2020, while research firm Prohibition Partners indicates that Oceania’s cannabis industry is expected to be worth US$1.55 billion by 2024; medicinal cannabis is expected to account for 40 percent of the industry.

Despite that growth, the country’s cannabis industry is still young. Recreational use is not yet in sight, and even medical access remains limited and highly regulated.

Keep reading... Show less

Australian Cannabis: Forecasts, Analysis and Expert Advice

Are you ready to start investing in Australia’s growing cannabis market?

Dive right in with our FREE Special Report, Australian Cannabis: Forecasts, Analysis and Expert Advice

Keep reading... Show less

Top News

Related News